Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) announced that its chief operating officer, chief medical officer and president of R&D, Dr David Roblin has resigned from the company with effect from 31 January 2020.
In a brief statement, Summit’s chief executive officer Glyn Edwards said: “David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical trials of ridinilazole for the treatment of C. difficile infection.”
“We are grateful to David for building a strong team that will continue to advance Summit’s important work and wish him all the very best in his future endeavours,” Edwards added.
The news comes a day after Summit revealed that American authorities have increased their financial backing of a programme developing a next-generation antibiotic.
The Biomedical Advanced Research and Development Authority (BARDA) is pumping a further US$8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection (CDI) taking the total value of the award to US$72.5mln.
The latest US cash injection will support a new clinical trial in adolescent patients, which in turn is expected to help with the new drug application for ridinilazole.